OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

2001 Individual Investigator Grant Recipient – Steven W. Johnson

Steven W. Johnson, Ph.D.
University of Pennsylvania
Characterizing Differential Gene Expression of Drug Sensitive and Resistant Ovarian Cancer

Project Summary

Ovarian cancer is responsible for nearly 15,000 deaths annually in the United States and is the fifth leading cause of death from cancer among women. Due to its relatively asymptomatic nature, the majority of ovarian cancer patients present with advanced-stage disease. Although this disease is relatively responsive to chemotherapy as compared to other types of cancer, most ovarian cancer patients who initially respond to chemotherapy eventually relapse and their disease is resistant to further treatment of this disease. Increased understanding of chemotherapeutic drug sensitivity/resistance mechanisms is important for the design of new therapeutic strategies. Dr. Johnson’s approach to understanding the resistance problem is to find the patterns of gene expression within tumor cells that are responsible for the drug resistance phenotype. He will use a technique that measures the expression of thousands of genes simultaneously in a panel of human ovarian cancer cell lines that are either drug sensitive or resistant. Genes identified will be tested for their ability to confer drug sensitivity or resistance. Findings should lead to new targets in ovarian cancer treatment.